Exciting News from Akero Therapeutics

Shares of Akero Therapeutics surged by 21% to $33.77 following the release of positive preliminary topline results from a Phase 2b study. The study evaluated the effectiveness and safety of their main product, efruxifermin, in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis with fibrosis stage 2 or 3.

Major Milestones Achieved

The study had previously met its primary endpoint by showing a one-stage improvement in fibrosis without worsening MASH after 24 weeks of treatment. The high-dose and low-dose groups both demonstrated significant improvement compared to the placebo arm.

Progress at Week 96

Fast forward to week 96, and the results are even more impressive. Response rates for the high-dose group were at 75%, while the low-dose group showed a response rate of 46%. These rates far exceeded the placebo response of just 24%.

Additional Successes

Not only did the study meet the primary endpoint, but it also achieved additional histology endpoints at week 96. A considerable number of patients experienced a two-stage improvement in fibrosis without worsening MASH.

Promising Outlook

Eefruxifermin was found to be well tolerated with no reported deaths. Serious adverse events were minimal and consistent across dose groups. The study is set to have a second biopsy after 96 weeks of treatment, with results expected in the first quarter of 2025.

Final Thoughts

These positive results showcase the potential of efruxifermin in treating metabolic dysfunction-associated steatohepatitis. With promising data and a focus on patient safety, Akero Therapeutics is making significant strides in the field.

Leave Comment